Omnimodus Elixír Kft.

Running trials

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· Phase 2· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Source

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  NCT06878261· Phase 3· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Source

• Enrolling by invitation

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· Phase 2· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Source

• Active, not recruiting

  Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

  NCT05097287· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD4 recruiting
• Asthma3 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Source

• Completed

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· Phase 3· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· Source

• Completed

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· Phase 3· Source

• Completed

  Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

  NCT05421598· Phase 2· Source

• Completed

  An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

  NCT05243680· Phase 3· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· Phase 3· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04701983· Phase 3· Source